Dr. Reddy’s successfully completes full set of clinical studies of its rituximab biosimilar for filing in the US, Europe

Dr. Reddy’s rituximab biosimilar has already been approved for marketing in India and over 25 emerging markets.

FPJ Web DeskUpdated: Friday, January 20, 2023, 11:31 AM IST
article-image
Dr. Reddy’s successfully completes full set of clinical studies of its rituximab biosimilar for filing in the U.S., Europe | Dr. Reddy

Dr. Reddy’s Laboratories Ltd, a global pharmaceutical company, announced that it has successfully completed the full set of clinical studies of its proposed rituximab biosimilar candidate, DRL_RI, for filing in highly regulated markets such as the United States, Europe and other regions.

DRL_RI is being developed as a biosimilar of rituximab, a cluster of differentiation 20 (CD20) directed cytolytic antibody for approval in the United States, European Union and other regions for various indications including treatment of adult patients with rheumatoid arthritis, non-Hodgkin's lymphoma, chronic lymphocytic leukaemia, pemphigus vulgaris, granulomatosis with polyangiitis and microscopic polyangiitis.

Dr. Reddy’s rituximab biosimilar has already been approved for marketing in India and over 25 emerging markets. The company undertook further clinical development to meet regulatory requirements of highly regulated markets. With the successful completion of these clinical studies, Dr. Reddy’s is now preparing to file Biologics License Application (BLA) / Marketing Authorisation Application (MAA) dossiers with various regulatory authorities globally.

Dr. Jayanth Sridhar, Global Head of Biologics at Dr. Reddy’s, said: “This is a very important milestone in our biosimilars journey. The successful completion and positive outcome of these clinical studies highlights our capability for global clinical development of biosimilar products for highly regulated and global markets. These results underscore our commitment to developing high quality biosimilars and reinforce the potential of DRL_RI as a safe and effective treatment option to patients across the globe.”

Dr. Reddy’s is currently collaborating with its partner Fresenius Kabi to commercialise its proposed biosimilar of rituximab in the United States. The company intends to commercialise the product in Europe and other geographies directly.

(If you have a story in and around Mumbai, you have our ears, be a citizen journalist and send us your story here. )

(To receive our E-paper on WhatsApp daily, please click here.  To receive it on Telegram, please click here. We permit sharing of the paper's PDF on WhatsApp and other social media platforms.)

RECENT STORIES

FPIs register steepest outflow in 7 months at Rs 28,852 cr in Jan

FPIs register steepest outflow in 7 months at Rs 28,852 cr in Jan

Rajeev Chandrasekhar says, guidelines for online gaming aimed at ensuring open, safe internet space

Rajeev Chandrasekhar says, guidelines for online gaming aimed at ensuring open, safe internet space

India's crude steel output grows by 5% in 2022; exports fall by 44%: Report

India's crude steel output grows by 5% in 2022; exports fall by 44%: Report

India Energy Week 2023: PM Modi to inaugurate event in Bengaluru, key energy initiatives to be...

India Energy Week 2023: PM Modi to inaugurate event in Bengaluru, key energy initiatives to be...

Infosys fires 600 freshers for failing internal test: Report

Infosys fires 600 freshers for failing internal test: Report